Patents by Inventor Alexandra Loew-Baselli
Alexandra Loew-Baselli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230360762Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.Type: ApplicationFiled: July 20, 2023Publication date: November 9, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kameswara Rao KUCHIMANCHI, Alexandra LOEW-BASELLI, Gerald SPOTTS, Myungshin OH, Michael Don HALE, Martin WOLFSEGGER
-
Patent number: 11749394Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.Type: GrantFiled: July 13, 2021Date of Patent: September 5, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Patent number: 11670409Abstract: Systems and methods for providing a clotting factor VIII (CFVIII) dosing regimen include collecting two blood samples from a patient after an infusion of CFVIII and determining a CFVIII clearance based on the two blood samples, and determining if a patient has a half-life greater than a predetermined threshold. A pharmacokinetic (PK) profile of the patient is determined using a Bayesian model of pharmacokinetic profiles of sampled patients having similar body weight or age of the patient. A first weight is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and a second weight, less than the first weight, is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is less than the predetermined threshold. A dosing regimen is determined for the patient based on the PK profile.Type: GrantFiled: April 13, 2017Date of Patent: June 6, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Publication number: 20210343375Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.Type: ApplicationFiled: July 13, 2021Publication date: November 4, 2021Inventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Patent number: 11081211Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.Type: GrantFiled: October 14, 2020Date of Patent: August 3, 2021Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Publication number: 20210027876Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.Type: ApplicationFiled: October 14, 2020Publication date: January 28, 2021Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Publication number: 20200312436Abstract: Systems and methods for providing a clotting factor VIII (CFVIII) dosing regimen include collecting two blood samples from a patient after an infusion of CFVIII and determining a CFVIII clearance based on the two blood samples, and determining if a patient has a half-life greater than a predetermined threshold. A pharmacokinetic (PK) profile of the patient is determined using a Bayesian model of pharmacokinetic profiles of sampled patients having similar body weight or age of the patient. A first weight is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and a second weight, less than the first weight, is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is less than the predetermined threshold. A dosing regimen is determined for the patient based on the PK profile.Type: ApplicationFiled: April 13, 2017Publication date: October 1, 2020Inventors: Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
-
Publication number: 20140379629Abstract: A system and method for providing a therapeutic plasma protein dosing regime includes determining a pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The example system and method also include determining a first dosing regime for a first specified dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient over a time period based at least upon the pharmacokinetic profile and determining a second dosing regime for a second specified dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient over the time period based at least upon the pharmacokinetic profile. The example system and method further include displaying the first dosing regime and the second dosing regime on a client device such that the first dosing regime is displayed in conjunction with the second dosing regime.Type: ApplicationFiled: June 20, 2014Publication date: December 25, 2014Inventors: Alexandra Loew-Baselli, Gerald Spotts, MyungShin Oh